ChemoCentryx, Inc. To Initiate Clinical Studies Of CCR2 Antagonist CCX915; Investigational New Drug Application On File; Studies To Commence By Year End

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Nov. 22, 2005--ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, announced that the company has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration to begin clinical studies of a proprietary small molecule inhibitor of the CCR2 chemokine receptor with which it expects to complete Phase I studies in 2006.

MORE ON THIS TOPIC